No Prescription

Alpha Index G

No Prescription » Products » Alpha Index G

List of Drugs:

A  B  C  D  E  F  G  H  I  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Z  #

Products G:

Gabapin Neurontin

Galamer Razadyne

Galvus Met Zomarist

Galvus Generic Vidagliptin

GASTRACTIV Vivadone

Geftinet Iressa

GEMEZ Factive

Genox Nolvadex

GenTeal Generic Hypromellose

Geodon (Ziprasidone)

Geroxalen Oxsoralen Ultra

Gestanin (Allyloestrenol)

G FLOX Gatiquin

GINETTE 35 Diane 35

Glez Glucotrol

Gliben Daonil

Gliclazide Glyade

Glimax Amaryl

Glimy Amaryl

GLINATE Starlix

Glinil M Glucovance

GlucoBalance

Glucobay Precose

Glucophage Fortamet

Glucophage (Metformin)

Glucotrol (Glipizide SR)

Glucotrol XL Generic Glipizide

Glucovance Generic Glyburide

GLUMET Glucophage

Glynase Glucotrol

Glynase XL Glucotrol XL

Gonaphene Clomid

GRANICIP KYTRIL

Graniset Kytril

Grief & Pining Formula

Grisactin (Griseofulvin)

GRISOVIN Fulvicin

Gumz-n-Teeth

Previous  Next

No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.